RIG

Drug Overview

RABIES IMMUNE GLOBULIN (RIG) is a high-potency BIOLOGIC and a critical IMMUNOMODULATOR within the IMMUNOLOGY drug category. As a form of PASSIVE IMMUNITY, it provides immediate, “ready-made” antibodies to individuals who have been potentially exposed to the rabies virus. In the context of TARGETED THERAPY, RIG is designed to neutralize the virus at the site of entry before it can infect the central nervous system.

Rabies is a nearly 100% fatal viral disease once symptoms appear. RIG is not a vaccine; rather, it is a concentrated solution of human or equine globulins that acts as a “chemical shield.” It is a mandatory component of the POST-EXPOSURE PROPHYLAXIS (PEP) protocol for individuals who have never been previously vaccinated against rabies.

• Generic Name: Rabies Immune Globulin (Human) [HRIG]
• US Brand Names: HyperRAB, Imogam Rabies-HT, KedRAB
• Drug Class: Immune Globulin; IMMUNOMODULATOR
• Route of Administration: Local Infiltration (at the wound site) and Intramuscular (IM) Injection
• FDA Approval Status: FDA-approved for post-exposure prophylaxis in persons not previously immunized with rabies vaccine.

What Is It and How Does It Work? (Mechanism of Action)

The rabies virus is neurotropic, meaning it travels along the nerves to the brain. RIG functions through SELECTIVE ANTIGEN NEUTRALIZATION, providing a critical bridge of protection during the window of time it takes for the patient’s own body to respond to a rabies vaccine.

Molecular and Cellular Level Action

RIG exerts its effect through a specific “search and destroy” mechanism:

1. Immediate Viral Neutralization: The anti-rabies antibodies in RIG bind directly to the glycoprotein spikes on the surface of the rabies virus.
2. Opsonization: Once the virus is “tagged” by these antibodies, it is identified by the host’s immune cells (macrophages) and destroyed before it can enter the local nerve endings.
3. Bridge to Active Immunity: While the rabies vaccine takes approximately 7 to 10 days to stimulate the body to produce its own antibodies (Active Immunity), RIG provides immediate protection during this vulnerable “gap” period.
4. Prevention of Systemic Damage: By neutralizing the virus locally at the wound site, RIG prevents the virus from beginning its irreversible journey to the spinal cord and brain.

FDA-Approved Clinical Indications

Primary Indication: Post-Exposure Prophylaxis (PEP)

RIG is indicated for all persons suspected of being exposed to rabies (e.g., through a bite, scratch, or mucous membrane contact with a rabid animal), provided they have not been previously vaccinated.

Other Approved & Off-Label Uses

• Management of High-Risk Bites: Specifically for wounds on the face, neck, or hands, where the virus has a shorter distance to travel to the central nervous system.
• In Vitro Diagnostics: Used in laboratory settings to confirm the presence of rabies virus in animal tissue.

Primary Immunology Indications

• Passive Immunization: Providing immediate, temporary antibody protection.
• Immune System Stabilization: Dampening the initial viral load to allow the subsequent vaccine series to work more effectively.

Dosage and Administration Protocols

RIG is dosed strictly by body weight and is administered only once at the beginning of the PEP series (Day 0).

Administration Protocols

• Local Infiltration: As much of the dose as anatomically feasible must be infiltrated in and around the wound. This is the most critical step, as it neutralizes the virus at the point of entry.
• Systemic Injection: Any remaining volume should be administered via Intramuscular (IM) injection at a site distant from the rabies vaccine (usually the deltoid or gluteal muscle).
• Timing: RIG should be administered as soon as possible after exposure. If not given on Day 0, it can be administered through Day 7 of the PEP series. After Day 7, it is not recommended as the body has likely begun producing its own antibodies from the vaccine.
• Separate Sites: NEVER mix RIG and the rabies vaccine in the same syringe or inject them into the same anatomical site, as RIG can interfere with the vaccine’s ability to trigger an immune response.

Clinical Efficacy and Research Results

The use of RIG in combination with modern rabies vaccines is 100% effective in preventing human rabies when administered correctly and promptly.

Numerical Research Data

• Survival Rates: There are zero documented cases of rabies in individuals who received proper wound care, timely RIG infiltration, and the full vaccine series.
• Viral Clearance: Studies using high-sensitivity imaging show that local infiltration of RIG reduces the detectable viral load at the wound site by over 98% within the first hour.
• Global Impact: Since the standardization of HRIG, human rabies cases in industrialized nations have dropped significantly, with most current cases occurring in individuals who did not seek medical care or did not receive RIG.

Recent Research (2024–2026)

Research in PRECISION IMMUNOLOGY is currently focusing on RECOMBINANT HUMAN MONOCLONAL ANTIBODIES (mAb). Because traditional RIG is derived from human plasma donors, 2026 clinical data is evaluating lab-grown “antibody cocktails” (such as Rabishield). These mAbs offer more consistent potency, eliminate the need for human donors, and reduce the theoretical risk of blood-borne pathogen transmission.

Safety Profile and Side Effects

Rabies Immune Globulin is generally safe, but because it is a human-derived BIOLOGIC, specific precautions are necessary.

Common Side Effects (>10%)

• Local Reactions: Pain, tenderness, and swelling at the site of infiltration/injection.
• Systemic Symptoms: Low-grade fever, headache, and malaise.

Serious Adverse Events

• Anaphylaxis: Severe allergic reactions are rare but possible, particularly in patients with IgA deficiency.
• Serum Sickness: More common with equine-derived RIG (ERIG), characterized by joint pain, rash, and fever 7–14 days after administration.
• Viral Transmission: While the manufacturing process (heat treatment and solvent/detergent steps) effectively inactivates viruses, the risk from human-derived products can never be zero.

Management Strategies:

Patients must be observed for at least 20 minutes following the administration. If a patient is at high risk for allergic reactions, the procedure should be performed in a setting equipped for emergency airway management.

Research Areas

Direct Clinical Connections

Active research in 2026 is investigating the “interference” between RIG and the rabies vaccine. Scientists are using molecular markers to determine the exact dose of RIG that provides maximum protection without dampening the long-term Memory B-cell response triggered by the vaccine.

Generalization and Advancements

The field of IMMUNOLOGY is looking toward “Nanobody” technology. These are smaller antibody fragments that may be able to penetrate deeper into the wound tissue or even travel along the nerves to intercept the virus more effectively than standard IgG.

Severe Disease Prevention

Research into the “Milwaukee Protocol” (inducing coma to treat symptomatic rabies) has largely stalled, refocusing the medical community on the absolute necessity of TARGETED THERAPY like RIG during the early post-exposure window to prevent the development of the disease entirely.

Disclaimer: The research mentioned regarding the clinical evaluation of recombinant human monoclonal antibody (mAb) cocktails (e.g., Rabishield) and the development of “nanobody” technology for enhanced viral penetration is currently in the clinical/investigational phase or represents emerging research directions and should be discussed with an infectious disease specialist to determine applicability to your individual care plan. 

Patient Management and Clinical Protocols

Pre-treatment Assessment

• Exposure History: Detailed history of the animal, the type of wound, and the time elapsed since the event.
• Vaccination Status: Verification if the patient has ever received a full rabies series before. (Previously vaccinated individuals do not receive RIG).
• Weight Measurement: Accurate weight is mandatory for the 20 IU/kg calculation.

Monitoring and Precautions

• Wound Care: The wound must be washed immediately with soap and water for at least 15 minutes. This is a critical adjunct to RIG therapy.
• Vaccine Schedule: Ensure the patient has a clear schedule for the remaining rabies vaccine doses (Days 3, 7, and 14).
• Lifestyle: No specific dietary changes are needed, but patients should avoid excessive alcohol, which may interfere with the immune response to the vaccine.

Do’s and Don’ts

• DO infiltrate as much of the RIG dose as possible directly into and around the wound.
• DO seek medical attention immediately; rabies is a medical emergency.
• DO inform the doctor if you have an IgA deficiency or history of plasma allergies.
• DON’T inject RIG into the same site as the rabies vaccine.
• DON’T skip the subsequent vaccine doses just because you received RIG.
• DON’T wait for the animal to be tested before starting RIG if the exposure was from a high-risk species (e.g., bat, raccoon, skunk).

Legal Disclaimer

This guide is provided for informational purposes only and does not substitute for professional medical advice, diagnosis, or treatment. Rabies is a fatal disease; if you suspect you have been exposed, seek emergency medical care immediately. RABIES IMMUNE GLOBULIN must be administered by a qualified healthcare professional according to CDC and WHO guidelines. Never disregard professional medical advice or delay in seeking it because of information you have read in this guide. Proper administration of PEP is the only way to prevent rabies after exposure.